Redouble AI

What do they actually do

Redouble AI provides a platform that layers on top of a company’s LLM workflows to cut down the amount of expert human review required in high‑stakes, regulated processes. It automatically drafts or analyzes content, routes only the riskiest items for human review, learns from reviewer edits, and maintains full audit trails and access controls so teams can prove who reviewed what and why redouble.ai/implementation redouble.ai/solutions.

They sell via demos and tailored pilots directly to regulated enterprises rather than self‑serve signups today, and they offer cloud, on‑prem, or hybrid deployments without training models on customer data redouble.ai redouble.ai/implementation. YC lists them as S24 with a first set of paying clients and revenue ycombinator.com/companies/redouble-ai.

Who are their target customer(s)

• Clinical/Regulatory Operations lead at a biopharma company: Weeks of expert time are spent reviewing trial reports and submissions, and they must maintain a verifiable approval record for regulators. They want faster drafting with auditability intact redouble.ai/implementation redouble.ai/solutions.
• Pharmacovigilance or Medical Monitoring manager in healthcare/medical‑device: Teams manually triage high volumes of safety reports and need to surface anomalies quickly; missed flags create regulatory risk. They need automated triage with oversight and reviewer monitoring redouble.ai/implementation.
• Claims Operations manager at an insurer: Claims processing requires expert judgment across many documents, causing bottlenecks and labor costs while auditors require traceable decisions. They need to reduce human touches on routine items with strong RBAC and audit logs redouble.ai/implementation redouble.ai/solutions.
• Head of Fund Operations or Compliance at VC/PE firms: Fund reporting, deal docs, and compliance checks need consistent standards and clear approval records for audits and LPs. They want standardized drafts, captured reviewer edits, and demonstrable review trails redouble.ai/solutions ycombinator.com/companies/redouble-ai.
• IT/Security lead at a regulated enterprise: They must integrate new tools with existing IAM and data‑residency policies and avoid model training on sensitive data. They want on‑prem/hybrid options and enterprise integrations with strict data controls redouble.ai/implementation.

How would they acquire their first 10, 50, and 100 customers

• First 10: Founder‑led, paid pilots with Clinical/Regulatory, Pharmacovigilance, Claims Ops, or Fund Ops leads. Solve one high‑value workflow, measure time‑saved and audit metrics, accept bespoke integrations, and convert pilots to enterprise contracts using clear SOWs and pilot‑to‑contract pricing.
• First 50: Productize the best‑performing pilots into 3–5 vertical templates and add 1–2 industry AEs for targeted outbound using pilot case studies. Start partnerships with niche consultancies/CROs and one SI to co‑sell and reduce implementation friction.
• First 100: Launch a self‑service pilot template and turnkey implementation playbook with a small CS team focused on fast time‑to‑value and expansion. Broaden channels (GxP consultants, compliance software partners, specialty SIs), secure required enterprise certifications, and provide a one‑page security/procurement packet to speed approvals.

What is the rough total addressable market

Top-down context:

Redouble targets software spend where regulated, human‑review‑heavy workflows live: clinical‑trial support (~$11.1B), pharmacovigilance (~$0.21B), insurance claims (~$42.4B), and fund accounting (~$3.5B), totaling ~ $57B; YC cites a narrower $11B figure as their public focus Grand View Research Grand View Research TBRC GMI Insights YC.

Bottom-up calculation:

A realistic near‑term SAM is the subset of those markets where outputs require human sign‑off and audited controls, estimated at 10–25% of ~$57B, or roughly $6–14B. This aligns with YC’s narrower framing of the opportunity YC.

Assumptions:

• Summed component markets approximate an upper‑bound TAM; some overlap across categories is possible.
• Only 10–25% of total software spend requires audited, human‑in‑the‑loop review that Redouble directly targets.
• Enterprise pilots and integration needs constrain near‑term capture versus self‑serve SaaS.

Who are some of their notable competitors

• Veeva Vault (Veeva Systems): Life sciences content and regulatory management platform with workflows and audit trails used for submissions and quality processes—an incumbent system Redouble would need to integrate with or displace in biopharma veeva.com.
• Oracle Argus Safety: Pharmacovigilance software for adverse‑event intake, triage, and reporting; a core system of record in drug safety where Redouble’s triage and review orchestration may overlap oracle.com.
• Guidewire ClaimCenter: Enterprise claims management platform for insurers with workflow automation and audit features—often the backbone for claims operations that Redouble might augment guidewire.com.
• eFront (BlackRock): Private markets/fund operations and compliance software used by PE/VC firms; relevant where Redouble targets fund reporting and review standardization efront.com.
• Hyperscience: AI document processing with human‑in‑the‑loop for regulated industries; overlaps in automating review of document‑heavy workflows while maintaining control and accuracy hyperscience.com.